Accueil > BIGG > Résultat de la recherche

    Résultats: 4

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged 2 through 18 years with underlying medical conditions

    MMWR recomm. rep; 72 (39), 2023
    On June 22, 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended use of 20-valent pneumococcal conjugate vaccine (PCV20 [Prevnar 20, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.]) as an option to 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sh...
    Vaccin antipneumococcique conjugué heptavalent/usage thérapeutique, Infections à pneumocoques/prévention et contrôle, Immunogénicité des vaccins, Comorbidité
    Texte intégral

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 years

    MMWR recomm. rep; 72 (39), 2023
    On June 22, 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended use of 20-valent pneumococcal conjugate vaccine (PCV20 [Prevnar 20, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.]) as an option to 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sh...
    Vaccin antipneumococcique conjugué heptavalent/usage thérapeutique, Infections à pneumocoques/prévention et contrôle, Immunogénicité des vaccins
    Texte intégral

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer RSVpreF Vaccine (ABRYSVO)

    MMWR recomm. rep; 79 (29), 2023
    A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer Respiratory Syncytial Virus (RSV) preF vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on June 21, 2023. GRADE evidence type indicates th...
    Immunogénicité des vaccins/immunologie, Vaccins antigrippaux/usage thérapeutique, Infections à pneumocoques/prévention et contrôle, COVID-19/prévention et contrôle, Virus respiratoire syncytial humain/immunologie
    Texte intégral

    GRADE: PCV15 use in children aged 2–18 years with certain underlying medical conditions that increase the risk of pneumococcal disease

    MMWR recomm. rep; 71 (37), 2022
    On June 22, 2022, ACIP recommended use of 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sharp & Dohme LLC]) as an option for pneumococcal conjugate vaccination for persons aged <19 years according to currently recommended PCV13 dosing and schedules. A systematic review and Grading o...
    Vaccins antipneumococciques/usage thérapeutique, Infections à pneumocoques/prévention et contrôle, Facteurs de risque
    Texte intégral